Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2191 • ACR Convergence 2025
Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course
Ranjan Gupta, Rudra Prosad Goswami and Anju Mohan, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases are impacted by their timely diagnosis, institution of correct treatment, management of complications and rigorous joint preservation strategies. The…
Abstract Number: 1943 • ACR Convergence 2025
Searching for subclinical synovitis and erosions in seropositive palindromic rheumatism: the added value of the ultrasonographic study of feet
Andrés Ponce¹, Cynthia Vanesa del Valle Rojas², nuria Sapena³, Georgina Novell³, anastasia Motcritcaia³, Beatriz Frade Sosa⁴, Juan Camilo Sarmiento-Monroy⁵, Vicenç Torrente-Segarra⁶, Julio Ramirez⁷, Virginia Ruiz-Esquide⁸, ana Belen Azuaga³, Francisco Vilchez³, Sandra Farietta³, Patricia Corzo⁹, Juan Cañete¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁸, ¹Hospital Clinic, Barcelona, Spain, ²Consorci Sanitari Alt Penedès-Garraf, Barcelona, Catalonia, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ⁷Clinic Barcelona Hospital Universitari, Barcelona, Catalonia, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Rheumatology Department, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Palindromic rheumatism (PR) is characterized by intermittent episodes of arthritis or periarthritis, and it can progress to rheumatoid arthritis (RA), particularly in patients with…
Abstract Number: 1779 • ACR Convergence 2025
Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
Wenxian Zhou¹, Hannah Johnson², Michael Duryee², Engle Sharp², Carlos Hunter², Tate Johnson², Mabruka Alfaidi², Daniel Anderson³, Kishore Bidasee², Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ^30587964, Durham, NC
Background/Purpose: Endothelial cell (EC) dysfunction is a key driver of cardiovascular (CV) complications in rheumatoid arthritis (RA), yet mechanisms underlying EC dysfunction in RA are…
Abstract Number: 1692 • ACR Convergence 2025
Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis
Ken Yasaka¹, Nida Pellett², Daria Krenitsky¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY
Background/Purpose: It has been proposed that the mucosal environment is associated with the pathogenesis of rheumatoid arthritis (RA). In addition to gut dysbiosis, intestinal barrier…
Abstract Number: 1387 • ACR Convergence 2025
Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
Jeffrey Curtis¹, Emily Holladay², Antton Egana³, Anjana Lalla³, Yujie Su⁴, Fenglong Xie⁵, Amy Mudano⁴, Shanette Daigle⁴ and Sara McCoy⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Wisconsin–Madison, Madison, WI
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
Abstract Number: 1359 • ACR Convergence 2025
Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Maya Khasho¹, Ahmad Alomari², Reem Elmusa³ and Rafal Ali⁴, ¹University of central florida, Gainesville, FL, ²UCF- North Florida hospital, Gainesville, FL, ³UCF/ HCA - North florida hospital, Gainesville, FL, ⁴Jefferson Einstein Philadelphia, Lansdale, PA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease affecting synovial joints, often leading to joint destruction if untreated. Disease-modifying antirheumatic drugs (DMARDs), including Janus…
Abstract Number: 1342 • ACR Convergence 2025
The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Saskia Truijen¹, Annelies Boonen¹, Sofia Ramiro² and Marloes van Onna¹, ¹Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: As the population ages, rheumatologists will increasingly care for older persons with rheumatoid arthritis (RA). Aging comes with specific challenges of which rheumatologists are…
Abstract Number: 1325 • ACR Convergence 2025
Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Punyasha Roul², Grant Cannon³, Gary Kunkel⁴, Beth Wallace⁵, Isaac Smith⁶, John Richards⁷, Katherine Wysham⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Joshua Baker¹³, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶Duke University Hospital, Durham, NC, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The mechanisms of heart failure (HF) risk in RA remain incompletely understood. HF with preserved ejection fraction (HFpEF) is over-represented in RA, which may…
Abstract Number: 1309 • ACR Convergence 2025
Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis
Christina Printzis¹, Keerthana Nagesh Prabhu², Regina Sakalyte³, Sigita Stropuviene³ and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Washington University in St. Louis, St Louis, MO, ³Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Clinic of Rheumatology, Orthopedics Traumatology and Reconstructive Surgery, Vilnius, Lithuania
Background/Purpose: A broad range (6-55%) of patients classified as having undifferentiated arthritis (UA) tend to progress to rheumatoid arthritis (RA), suggesting that UA in these…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 1034 • ACR Convergence 2025
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Elena Joerns¹, Jeffrey Sparks², Cynthia Chelf¹, Cynthia Crowson³, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Healthy dietary patterns are associated with many health benefits, including lower cardiovascular disease, mortality, and rheumatoid arthritis (RA) disease activity. Therefore, we aimed to…
Abstract Number: 0978 • ACR Convergence 2025
IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
Bennie Heeswijk¹, Margot Bongenaar¹, Nadine Davelaar¹, Pascal de Jong¹, Hannah den Braanker¹, Radboud Dolhain¹ and Erik Lubberts², ¹Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ²Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Regulatory T cells (Tregs) are essential for maintaining immune tolerance and limiting excessive immune responses. However, Tregs show high levels of heterogeneity and plasticity,…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 0797 • ACR Convergence 2025
Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining
Sonia Presti¹, Kseniia Anufrieva², Ce Gao³, Sean Prell², Philip Blazar², Jeffrey Lange², Morgan Jones², Mihir Wechalekar⁴, Michael Brenner², Ilya Korsunsky⁵, Shideh Kazerounian² and Kevin Wei⁶, ¹Standford University, Stanford, ²Mass General Brigham, Boston, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: The synovial lining is crucial for joint homeostasis, forming a barrier and producing lubricants through specialized fibroblasts. These fibroblasts differ from sublining fibroblasts, which…
Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
MIDHUN SAKRAVARTHY JALANATHAN¹, Mehdi Ali Mirza¹, Vijaya prasanna Parimi², Seethalakshmi S¹ and Tejaswini Ramineni³, ¹ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].